Olaparib efficacy in patients with germline BRCA-mutated, HER2-negative metastatic breast cancer: Subgroup analyses from the phase III OlympiAD trial.

ABSTRACT

In the primary analysis of the phase III OlympiAD trial, olaparib significantly prolonged progression-free survival (PFS) vs chemotherapy treatment of physician's choice (TPC) in patients with germline BRCA-mutated (gBRCAm), HER2-negative metastatic breast cancer (mBC). We report subgroup analyses for the final analysis at a median OS follow-up of 18.9 months (olaparib) and 15.5 months (TPC). Patients (N = 302) with gBRCAm, HER2-negative mBC and ≤2 previous lines of chemotherapy for mBC were randomized 21 to open-label olaparib (300 mg twice daily) or TPC. All subgroup analyses were prespecified except site of metastases. Investigator-assessed median PFS was 8.0 months (95% confidence interval [CI] 5.8-8.4; 176/205 events) for olaparib and 3.8 months (95% CI 2.8-4.2; 83/97 events) for TPC (hazard ratio 0.51, 95% CI 0.39-0.66). In subgroup analyses, median PFS hazard ratios (95% CI) favored olaparib hormone receptor status (triple-negative 0.47, 0.32-0.69; hormone receptor-positive 0.52, 0.36-0.75); gBRCAm (BRCA1 0.49, 0.35-0.71; BRCA2 0.49, 0.33-0.74); site of metastases (visceral/CNS 0.53, 0.40-0.71; non-visceral 0.45, 0.23-0.98); prior chemotherapy for mBC (yes 0.51, 0.38-0.70; no 0.49, 0.30-0.82); prior platinum-based chemotherapy for BC (yes 0.49, 0.30-0.83; no 0.50, 0.37-0.69); progressive disease at randomization (yes 0.48, 0.35-0.65; no 0.61, 0.36-1.07). Investigator-assessed objective response rates were higher across all subgroups with olaparib (35-68%) vs TPC (5-40%). Global health status/health-related quality of life increased in all subgroups with olaparib vs decreased/no change with TPC. These data confirm the consistency of olaparib benefit across patient subgroups in OlympiAD.